Product Images Camzyos

CAMZYOS™ is a medication in capsule form containing 15mg of mavacamten. It is recommended to consult prescribing information for accurate dosing. It is distributed by MyoKardia Inc., which is a subsidiary of Bristol Myers Squibb. Each bottle contains 30 capsules and must be kept out of reach of children. It should not be used if the seal is broken or missing. The medication should be stored at a temperature between 20°C to 25°C (68°F to 77°F) with excursions permissible to between 15°C to 30°C (between 59°F to 86°F).*

CAMZYOST is a medication that comes in capsule form with each capsule containing 5mg of Mavacamten. The medication is distributed by a company called MyoKardia, Inc., which is a subsidiary of Bristol Myers Squibb. The medication comes in a bottle that contains 30 capsules and it is advisable to keep it out of reach of children. It is essential to follow the recommended dosage as stated in the prescription information. Additionally, it is not advisable to use the medication if the seal on the bottle is broken or missing. It is recommended to store the medication at a temperature between 20°C to 25°C but excursions are allowed between 15°C to 30°C.*

This text is a chart presenting the percentage of subjects experiencing a change in post-exercise LVOT gradient below a certain threshold for the drug Mavacamten compared to a placebo. The x-axis shows the threshold for the change in post-exercise LVOT gradient in mmHg from baseline to week 30. The y-axis shows the percentage of subjects. There is also a graph with a range of -140 to 60 on the x-axis and 0 to 100 on the y-axis.*

The text is describing a chart that shows the percentage of subjects with a change in pVO2 above a certain threshold at different points in time. The x-axis is denoted in units of the threshold for change in pVO2 (mL/kg/min) from baseline to week 30. However, there is not enough information to explain what pVO2 or Mavacamten refer to.*

The text describes a figure displaying the percentage of subjects with a change in HCMSAQ Shortness of Breath score below a certain threshold. The threshold is indicated on the x-axis, with negative and positive values, and the percentage of patients achieving a certain level of response is indicated on the y-axis. The figure shows a cumulative distribution, with higher percentages of patients achieving lower levels of response. The figure is likely related to the evaluation of a medication or treatment called Mavacamten.*

The text describes a figure showing the percent of subjects with a change in KCCQ-23 Clinical Summary Score > Threshold. The figure displays the cumulative percentage of patients achieving a certain level of response. No additional information is available.*

This text describes the recommended actions for adjusting medication dose based on the left ventricular ejection fraction (LVEF) and Valsalva LVOT gradient of a patient. If the LVEF is <50%, treatment should be interrupted. If the LVEF is 50-55% or >55% with a gradient of <30 mmHg, the same dosage can be maintained and reviewed after 12 weeks. If the LVEF is >55% with a gradient of 230 mmHg, the dosage should be increased and the clinical status and ECHO should be rechecked after 4 weeks. After 12 weeks of treatment on the same dose level, further up-titration is allowed.*

This is a table that shows the percentage of patients meeting the primary endpoint in different subgroups, with mavacamten and placebo, for a certain clinical trial. The different subgroups are categorized based on age, sex, body mass index, LVEF at baseline, NYHA class at baseline, beta-blocker usage at baseline, and type of exercise testing. The results show that mavacamten is better than placebo for all subgroups.*

The text describes a treatment plan for interrupting medication at a certain dosage level and restarting at a lower level for the purpose of checking ECHO parameters. If the LVEF (left ventricular ejection fraction) is above 50%, the treatment can be continued at the same dose. If the LVEF is below 50% twice at the 2.5mg daily dose level, then the medication should be permanently discontinued. The plan recommends rechecking the clinical status and ECHO in 4 weeks and following Figure 2.*

This is a medication description. The name of the medication is not provided, but the capsules contain 2.5 mg of mavacamen. The medication should be stored between 20°C and 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (between 59°F to 85°F). It also mentions to see USP for controlled oom temperature.*

This is a description of a medication with the name NDG 73625-113-11. The medication is in capsule form and each capsule contains 10mg mavacamten. It is manufactured by Bristol Myers Squibb and should be stored at a temperature of 20°C to 25°C. The medication should not be stored outside the range of 15°C to 30°C (59°F to 86°F) as specified by USP for controlled room temperature.*